Prognostic significance of acquired copy-neutral loss of heterozygosity in acute myeloid leukemia

Cancer

Volumn 121, Issue 17, 2015, Pages 2900-2908

  Gronseth, Christine M ^a   McElhone, Scott E ^a   Storer, Barry E ^b   Kroeger, Kathleen A ^a   Sandhu, Vicky ^b   Fero, Matthew L ^a,b,c   Appelbaum, Frederick R ^a,b,c   Estey, Elihu H ^a,b,c   Fang, Min ^a,b,d  

^a SEATTLE CANCER CARE ALLIANCE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

acute myeloid leukemia (AML); chromosome genomic array testing (CGAT); copy neutral loss of heterozygosity (cnLOH); prognosis

Indexed keywords

DNA;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; BLOOD SAMPLING; BONE MARROW; CANCER PROGNOSIS; CANCER REGRESSION; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME GENOMIC ARRAY TESTING; CONTROLLED STUDY; CYTOGENETICS; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GENE DOSAGE; HETEROZYGOSITY LOSS; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; COPY NUMBER VARIATION; GENETICS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DNA COPY NUMBER VARIATIONS; FEMALE; GENE DOSAGE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84939572887     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29475     Document Type: Article

References (23)

1. Mrozek K, Marcucci G, Nicolet D, et al., Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2012; 30: 4515-4523.
2. Slovak ML, Kopecky KJ, Cassileth PA, et al., Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000; 96: 4075-4083.
3. Grimwade D, Walker H, Oliver F, et al., The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998; 92: 2322-2333.
4. Fang M, Storer B, Estey E, et al., Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation. Blood. 2011; 118: 1490-1494.
5. Breems DA, Van Putten WL, De Greef GE, et al., Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008; 26: 4791-4797.
6. Medeiros BC, Othus M, Fang M, Roulston D, Appelbaum FR,. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood. 2010; 116: 2224-2228.
7. Bullinger L, Kronke J, Schon C, et al., Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis. Leukemia. 2010; 24: 438-449.
8. Nowak D, Klaumuenzer M, Hanfstein B, et al., SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3. Genes Chromosomes Cancer. 2012; 51: 756-767.
9. Yi JH, Huh J, Kim HJ, et al., Adverse prognostic impact of abnormal lesions detected by genome-wide single nucleotide polymorphism array-based karyotyping analysis in acute myeloid leukemia with normal karyotype. J Clin Oncol. 2011; 29: 4702-4708.
10. Kuhn MW, Radtke I, Bullinger L, et al., High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. Blood. 2012; 119: e67-e75.
11. Xu X, Johnson EB, Leverton L, et al., The advantage of using SNP array in clinical testing for hematological malignancies-a comparative study of three genetic testing methods. Cancer Genet. 2013; 206: 317-326.
12. Tiu RV, Gondek LP, O'Keefe CL, et al., New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. J Clin Oncol. 2009; 27: 5219-5226.
13. O'Keefe C, McDevitt MA, Maciejewski JP,. Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies. Blood. 2010; 115: 2731-2739.
14. Mohamedali AM, Alkhatabi H, Kulasekararaj A, et al., Utility of peripheral blood for cytogenetic and mutation analysis in myelodysplastic syndrome. Blood. 2013; 122: 567-570.
15. Sabattini E, Bacci F, Sagramoso C, Pileri SA,. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010; 102: 83-87.
16. Shaffer LG, Slovak ML, Campbell LJ,. An International System for Human Cytogenetic Nomenclature (2009). Basel, Switzerland: S. Karger Publishers Inc; 2009.
17. Shaffer LG, McGowan-Jordan J, Schmid M,. An International System for Human Cytogenetic Nomenclature (2013). Basel, Switzerland: S. Karger Publishers Inc; 2013.
18. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
19. Cox DR,. Regression models and life tables (with discussion). J R Stat Soc B. 1972; 34: 187-220.
20. Fitzgibbon J, Smith LL, Raghavan M, et al., Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res. 2005; 65: 9152-9154.
21. Jasek M, Gondek LP, Bejanyan N, et al., TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p. Leukemia. 2010; 24: 216-219.
22. Stirewalt DL, Pogosova-Agadjanyan EL, Tsuchiya K, Joaquin J, Meshinchi S,. Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AML. Blood Cancer J. 2014; 4: e208.
23. Shiba N, Hasegawa D, Park MJ, et al., CBL mutation in chronic myelomonocytic leukemia secondary to familial platelet disorder with propensity to develop acute myeloid leukemia (FPD/AML). Blood. 2012; 119: 2612-2614.